Journal
AMERICAN JOURNAL OF TRANSPLANTATION
Volume 23, Issue 3, Pages 423-428Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.ajt.2022.11.002
Keywords
COVID-19; monoclonal antibody; tixagevimab; cilgavimab; organ transplant; Omicron variant
Categories
Ask authors/readers for more resources
Neutralizing antibody (nAb) responses are weakened in solid organ transplant recipients (SOTRs) despite being fully vaccinated. Preexposure prophylaxis (PrEP) with the antibody combination tixagevimab and cilgavimab (T+C) may enhance immune protection, but its activity and durability against Omicron sublineages BA.4/5 in fully vaccinated SOTRs have not been determined. Most fully vaccinated SOTRs receiving T+C PrEP achieved neutralization against BA.4/5, but nAb activity commonly declined after 3 months. It is crucial to evaluate the optimal dose and interval of T+C PrEP to maximize protection against emerging variants.
Neutralizing antibody (nAb) responses are attenuated in solid organ transplant recipients (SOTRs) despite severe acute respiratory syndrome-coronavirus-2 vaccination. Preexposure prophylaxis (PrEP) with the antibody com-bination tixagevimab and cilgavimab (T+C) might augment immunoprotection, yet in vitro activity and durability against Omicron sublineages BA.4/5 in fully vaccinated SOTRs have not been delineated. Vaccinated SOTRs, who received 300 + 300 mg T+C (ie, full dose), within a prospective observational cohort submitted pre and post -injection samples between January 31, 2022, and July 6, 2022. The peak live virus nAb was measured against Omicron sublineages (BA.1, BA.2, BA.2.12.1, and BA.4), and surrogate neutralization (percent inhibition of angiotensin-converting enzyme 2 receptor binding to full length spike, validated vs live virus) was measured out to 3 months against sublineages, including BA.4/5. With live virus testing, the proportion of SOTRs with any nAb increased against BA.2 (47%-100%; P < .01), BA.2.12.1 (27%-80%; P < .01), and BA.4 (27%-93%; P < .01), but not against BA.1 (40%-33%; P = .6). The proportion of SOTRs with surrogate neutralizing inhibition against BA.5, however, fell to 15% by 3 months. Two participants developed mild severe acute respiratory syndrome-coronavirus-2 infection during follow-up. The majority of fully vaccinated SOTRs receiving T+C PrEP achieved BA.4/5 neutralization, yet nAb activity commonly waned by 3 months postinjection. It is critical to assess the optimal dose and interval of T+C PrEP to maximize protection in a changing variant climate.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available